CDMO Services

About Bright Cell

Bright Cell is a private, early-stage biotech firm founded in 2018 and headquartered in Boston, with an operational address in Irvine, California. The company is developing a pipeline of stem cell-based therapeutic candidates, some of which are in US FDA-regulated clinical trials, while also offering commercial services in R&D, CDMO, and cell banking. Its business model combines therapeutic development with service revenue, positioning it in the high-growth regenerative medicine market, though it faces significant risks common to pre-revenue biotech ventures, including clinical trial outcomes and funding needs.

About Ectica Technologies

Ectica Technologies is a privately held spin-off from ETH Zurich and the University of Zurich, founded to commercialize innovative hydrogel technologies for pre-clinical drug discovery. The company's patented 3DProSeed® platform creates synthetic, animal-free models of the tumor stroma, addressing the critical need to incorporate tumor-stroma interactions into high-content screening assays. By providing physiologically relevant yet automation-compatible models, Ectica targets the growing demand for more predictive in vitro systems in oncology and fibrosis research. Its business model combines product sales (StromaLine models) with contract development and manufacturing services for tailored hydrogel formulations.

About Laboratorios Atral

Laboratorios Atral is an established, private Portuguese pharmaceutical firm with a dual business model encompassing proprietary product commercialization and contract services. The company has a historical legacy in antibiotic production and now maintains a portfolio of branded generic and specialty medicines, primarily in ophthalmology and dermatology. Its strategic focus includes expanding its service offerings as a CDMO and leveraging its regulatory expertise to commercialize products across Europe, Latin America, the Middle East, and Africa. Atral's operations are underpinned by a full-spectrum in-house infrastructure covering R&D, production, quality control, and pharmacovigilance.

Therapeutic Areas

Other N/A - Service Drugs